Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk
If You've had a Heart Attack or Stroke, Your Risk of Having Another Cardiovascular Event is Nearly One in Three(1)
Cholesterol 911 Urges These High-Risk Patients to See the Emergency in High Cholesterol and Talk to Their Doctor About Ways to Reduce the Risk of Another Heart Attack and Stroke
THOUSAND OAKS, Calif., March 12, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched Cholesterol 911, a national initiative urging high-risk cardiovascular disease patients to reduce their risk of another heart attack or stroke by addressing their continued high LDL-C, or "bad" cholesterol. Comedian and television host Jay ...
Source: Amgen News Release - March 12, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces 2019 Second Quarter Dividend
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. The dividend will be paid on June 7, 2019, to all stockholders of record as of the close of business on May 17, 2019.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand th...
Source: Amgen News Release - March 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019, in Boston. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients su...
Source: Amgen News Release - March 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha ® (evolocumab) Across Multiple Patient Populations
Results From TAUSSIG Study Reinforce Repatha's Safety and Efficacy in Patients With Genetic Risk of High Cholesterol
Several Real-World Evidence Studies Highlight Continued Unmet Need and Suboptimal Treatment of High-Risk Cardiovascular Disease Patients
THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1 as well as a sub-analysis from the Repatha® (evol...
Source: Amgen News Release - March 6, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019
First Preclinical Data to be Presented on AMG 510, a First-in-Class KRASG12C Inhibitor for Solid Tumors
New Preclinical Data Evaluating AMG 757 to Highlight Half-Life Extended BiTE® Immunotherapy
AMG 176 Preclinical Data Showcase Potential in Combination With Standard of Care Treatments for Acute Myeloid Leukemia
THOUSAND OAKS, Calif., Feb. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 – April 3, 2019.
"At Amgen, we are searching for ...
Source: Amgen News Release - February 28, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Jury Upholds Amgen's Patents On Repatha ® (evolocumab)
THOUSAND OAKS, Calif., Feb. 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amgen's innovative Repatha® (evolocumab) product, that bind to a specific region on PCSK9 and reduce LDL-C levels in the body. This verdict follows a previous trial in March 2016 where Sanofi and Regeneron admitted infringement of Amgen's patents and where a prior jury also upheld the validity of Amgen's patents. The prior jury decision was partially rever...
Source: Amgen News Release - February 25, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF).
METEORIC-HF is designed to evaluate the effect of treatmen...
Source: Amgen News Release - February 21, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Reports Fourth Quarter And Full Year 2018 Financial Results
THOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include:
For the fourth quarter, total revenues increased 7 percent to $6.2 billion.
Product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth.
For the full year, total revenues increased 4 percent to $23.7 billion, with 3 percent product sales growth...
Source: Amgen News Release - January 29, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2018 financial results on Tuesday, Jan. 29, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Receives NMPA Approval For Repatha ® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events
Innovative LDL-C Lowering Treatment has now Been Approved for High-Risk Patients in China With Cardiovascular Disease
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization.
Low-density lipoprotein cholesterol (LDL-C) is one of the key modifiable risk factors for the development...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar candidate to RITUXAN® (rituximab), compared to rituximab in patients with moderate-to-severe rheumatoid arthritis. The results demonstrate that the study met its primary endpoint of pharmacokinetic (PK) si...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
European Commission Approves BLINCYTO ® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the First and Only Therapy for Minimal Residual Disease Approved in the European Union
Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission ...
Source: Amgen News Release - January 22, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY ™ (romosozumab)
Potential New Treatment Option for the Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies. Eighteen of 19 members voted yes fo...
Source: Amgen News Release - January 16, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
EVENITY ™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
EVENITY Approved to Reduce the Risk of Fractures and Increase Bone Mineral Density in Men and Postmenopausal Women With Osteoporosis at High Risk of Fracture
EVENITY in Japan is Being Co-Developed Through a Strategic Alliance With Amgen Astellas BioPharma
THOUSAND OAKS, Calif. and BRUSSELS, Belgium, Jan. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.1 Amgen and UCB are co-develo...
Source: Amgen News Release - January 8, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Makes All Repatha ® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
The Repatha Pre-Filled Syringe and Repatha Pushtronex® System are Now Available at a Reduced List Price of $5,850
Majority of Repatha Medicare Patients Now Have Access at a Significantly Lower Out-of-Pocket Cost
THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, all Repatha® (evolocumab) device options, including the Pre-Filled Syringe and Pushtronex® (on-body infusor with prefilled cartri...
Source: Amgen News Release - January 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
